ReviewTranslational andrology and urology2025
Personalized prostate biopsy protocols: enhancing cancer detection through tailored approaches-a narrative review.
Review in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.The Canadian journal of urology · 2026Article
- Urine-based PSMA detection for noninvasive prostate cancer diagnosis: recent advances, translational challenges, and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Traditionally, patients with positive magnetic resonance imaging (MRI) results [i.e., Prostate Imaging-Reporting and Data System (PI-RADS) ≥3] would have to undergo both targeted and systematic biopsies. The 2024 European Urology Association guidelines now recommend incorporating perilesional sampling with targeted biopsy; however, these recommendations have not yet been widely adopted. This review aims to examine recent advancements in personalized prostate biopsy techniques to enhance cancer detection through tailored approaches. Methods: We conducted a narrative review to highlight recent advancements in personalized prostate biopsy techniques, emphasizing the roles of serum prostate-specific antigen (PSA) levels, prostate volume (PV), PSA density (PSAD), region of interest (ROI), and PI-RADS scores. Key Content and Findings: This review discusses personalized prostate biopsy protocols, integrating PSA levels, PV, PSAD, and PI-RADS scores. Tumor localization can be refined using transrectal or transperineal approaches. For patients with lower PSA levels (4-19.99 ng/mL), smaller PSAD (<0.1 ng/mL/cc), or PI-RADS 3 lesions, a targeted plus systematic biopsy or regional saturation biopsy may be appropriate. For those with medium PSA levels (20-50 ng/mL), PSAD (0.1-0.2 ng/mL/cc), or PI-RADS 4 lesions, regional saturation biopsy is preferred. Targeted biopsy is recommended for higher PSA levels (>50 ng/mL), PSAD (>0.2 ng/mL/cc), or PI-RADS 5 lesions. Variability in cut-off values across studies precludes meta-analysis, limiting our work to a systematic review. Conclusions: Personalized prostate biopsy protocols considering PSA levels, PV, PSAD, ROI, and PI-RADS scores can improve prostate cancer detection accuracy. Further research and clinical validation are needed to optimize these personalized methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.